A look back at some of the year’s biggest milestones
January 16, 2020
The new decade is already upon us. That means there is no better time to look back on our immunomics highlights of last year. We are incredibly proud of 2019 and all that was accomplished. We launched new products, entered into new strategic partnerships, and got recognized as one of the most promising startups in Europe.
Delivering unique immune repertoire data handling solutions
ENPICOM brought a unique software solution to the market – the ImmunoGenomiX (IGX) Platform. Its robust data handling features allows life scientists and biopharma companies to discover valuable insights to improve the health of patients treated with immunotherapy or affected by immune system related diseases or conditions. As the development of the platform continues, we are adding more features and enhancements to it. The latest version (1.1) offers several speed improvements as well as a new quality assurance app (IGX-Inspect).
Learn more about the IGX Platform here.
Offering full IGX services to accelerate immunotherapy discovery and development
To deliver complete immune repertoire sequencing and data analysis services, we joined forces with DDL Diagnostic Laboratory. Now we can support organizations that don’t have the necessary expertise or capabilities in-house. Our full-service proposition includes sample preparation, sequencing, data analysis, and visualization. Besides, all of our service customers get 48-hour complimentary access to our SaaS platform which allows them to experience its extraordinary data mining power themselves.
Visit this page to learn more about our IGX services.
Accelerating innovation through strategic partnerships
BOM Brabant Ventures, NextGen Ventures, and Arches Capital jointly strengthened our ambition to become a global player in the field of immunomics. The investors’ support allowed us to finalize the IGX Platform development.
Moreover, we have established a fruitful collaboration with Cytura Therapeutics to develop a new biomarker for early cancer detection and received a joint MIT-Zuid R&D partnership subsidy.
Supporting scientific research
Our team had the honor to work together with some of the brightest minds in the biomedical field and contributed to the publication of the following scientific papers:
- T cell receptor next-generation sequencing reveals cancer-associated repertoire metrics and reconstitution after chemotherapy in patients with hematological and solid tumors (Journal of OncoImmunology, vol 8, 2019 – Issue 11)
- High-Throughput Immunogenetics Reveals a Lack of Physiological T Cell Clusters in Patients With Autoimmune Cytopenias (Frontiers in Immunoloy, 21 August 2019)
- Deep Sequencing of Bone Marrow Microenvironments of Patients With Del(5q) Myelodysplastic Syndrome Reveals Imprints of Antigenic Selection as Well as Generation of Novel T-Cell Clusters as a Response Pattern to Lenalidomide (Heamatologica July 2019 104: 1355-1364)
On top of that, we had the chance to attend several relevant events to connect with researchers in the market and share our knowledge. Make sure to check out the recordings of the presentations our team gave at Genomics live, World Vaccine Congress, and European Antibody Discovery Congress.
Visit our knowledge center for more online resources.
Getting the right people on the bus
In the past year, the ENPICOM team has doubled in size, growing from 10 to 20 employees, and we opened a satellite office in Amsterdam. We have built a top-class, diverse team of experts with the right combination of knowledge and expertise to jointly tackle the data analysis and software engineering challenges related to the field of immunomics.
Together with our scientific and strategic partners and supported by our investors, we develop tools and validate applications to truly bridge the gap between immune repertoire sequencing and the insights needed to improve human health.
Looking ahead
We want to thank you all for your continued support and partnership. We are excited to enter 2020 together and keep innovating with software products that help you advance your research, facilitate faster drug development, and eventually improve health outcomes for everyone.
Subscribe to the ENPICOM newsletter to get the latest news and content in 2020!
